ABSTRACT The prevalence ofatopic diseases and bronchial rcactivity to histamine and methacholine was determined in 36 patients with bronchiectasis and in 36 control patients matched for age, sex, and smoking history. There was no difference in the prevalence of asthma, other atopic diseases, family history of atopic diseases, or positive responses 4o skinprick tests (nine versus five) in the two groups. The prevalence of bronchial hyperreactivity, however, was significantly higher in the group with bronchiectasis than in the control group for both histamine (7 v 0 patients) and methacholine (6 v 0 patients). The group with bronchiectasis had more airflow obstruction (mean FEV, 67% predicted), but there was no correlation between spirometric indices and log PD20 (the log dose of histamine or methacholine causing a 20% fall in FEV,). This suggests that, although reduced airway calibre may be a factor underlying bronchial hyperreactivity in bronchiectasis, it is not the only mechanism. Further studies are needed to determine whether bronchial hyperreactivity has a causative role in the pathogenesis of bronchiectasis or whether it occurs as a result of the disease.
Introduction
Asthma and bronchial hyperreactivity may play a part in the aetiology and pathogenesis of bronchiectasis by reducing the efficacy of respiratory clearance mechanisms and thereby promoting microbial colonisation and inflammation.' This hypothesis is supported by studies that show an apparently high prevalence of atopic diseases, including asthma23 and bronchial hyperreactivity,2' in patients with bronchiectasis.
These studies, however, either were uncontrolled23 or used a small number of poorly matched subjects. 4 Using an equal number ofage and sex matched normal subjects, Murphy et al found no significant increase in the prevalence of atopy in 23 patients with bronchiectasis. Bronchial reactivity was not measured, however, and they did not control for cigarette smoking, a factor that may affect the prevalence of both atopy67 and bronchial reactivity.89
In view of the conflicting results and paucity of comparative data in well matched control subjects, we have studied the prevalence of atopy and bronchial hyperreactivity in 36 patients with bronchiectasis and in 36 control patients matched for age, sex, and smoking history.
Methods

PATIENTS
The study group consisted of 36 patients with bronchiectasis whose clinical diagnosis was confirmed by computed tomography with bronchography when necessary. None of the patients had cystic fibrosis, bronchopulmonary aspergillosis, or humoral immune deficiency; there was no attempt to select the patients by any other criterion. The mean duration of respiratory symptoms was 10 7 (SD 8-5, range 1-40) years. The extent of disease on the computed tomogram was estimated by dividing each lung into upper, middle, and lower zones (total six zones). The mean number of zones affected by bronchiectasis was 2-5 (SD 1-3, range [1] [2] [3] [4] [5] Lctivity to histamine or methacholine. different from the prevalence in normal controls with bronchiectasis were hyperreactive matched for age and sex. In this study we also matched (p < 0-01), six to methacholine (p < for smoking habit, a variable known to affect both ce to both agents, making a total of 10 atopy6" and bronchial reactivity.89 This was relatively 8ronchial hyperreactivity to one or both easy because most of our patients with bronchiectasis )-001). Of these 10 patients, only three were non-smokers or light smokers. After allowing for ;kinprick test responses. When a PD2, smoking, we did not find a significant difference in the 7-8 gmol was used as the cut off point, prevalence of atopy as defined by history or skinprick in the bronchiectasis group and one testing, though the numbers ofpatients with a positive control group had bronchial hyper-skin test response in the patients with bronchiectasis 0.01).
(nine) and the control patients (five) are small. Our
Lnt correlation was found between FEV, findings cast some doubt on the hypothesis that atopy and log PD2,, histamine or methacholine may have a role in the aetiology of bronchiectasis, or with bronchiectasis who had bronchial that it may occur as a result of prolonged bronchial y ( figure) . suppuration, though larger numbers of subjects are needed to clarify this point. In this study, bronchial reactivity was measured by the method of Yan et al," which has been shown to be studies report an apparently high simple, rapid, and reproducible." '3 Two different asthma (slightly over 20% 23) and atopy values of PD20H to define bronchial hyperreactivity to i 30% 16 to 42% 2) in patients with histamine were used for the analyses. The first dose, 5
This has been used as evidence to imol, was chosen because patients with asthma or le of asthma and an allergic diathesis as wheeze but not atopic controls had a PD20H of less ctors in bronchiectasis. In the absence of than 5 pmol in one study." The higher dose, 7-8 gmol, ;ts, however, these prevalence data are was chosen because it has been used to define bronerpret; comparison with published data chial hyperreactivity in patients with airflow obstrucpopulations does not take into account tion,"5 and this was the spirometric pattern found in diagnostic criteria. More importantly, our patients with bronchiectasis, even though only one bronchiectasis are likely to be a highly patient had asthma. For methacholine a value of 6 whose other characteristics may be very imol was used to define bronchial hyperreactivity those of the general population. These because a direct comparison between histamine and 11 illustrated by the study of Murphy et methacholine challenge in a community study using nd a very high prevalence of atopy in the method of Yan et al " showed the two agents to be bronchiectasis (52%), but this was not of similar potency. ' Prevalence ofasthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study hyperreactivity may reflect the reduction in airway calibre as in smokers.'5 Although most of our patients were non-smokers, airflow obstruction may still be the mechanism underlying the increased prevalence of bronchial hyperreactivity. There was no correlation, however, between the indices of airflow obstruction and log PD20 in our patients with bronchiectasis and bronchial hyperreactivity (figure)-although, with the small number of patients and the rather narrow range of values, a significant relationship may have been missed. A preliminary study reported that intensive antibiotic treatment reduced the degree ofbronchial hyperreactivity in patients with bronchiectasis without significantly affecting baseline spirometric values.'8 Thirdly, bronchial hyperreactivity may result from increased access to toxins through infected or inflamed bronchial mucosa, with consequent alteration in smooth muscle tone and autonomic neural regulation.'9 This is supported by the finding that pulmonary epithelial permeability is increased in patients, with bronchiectasis,20 and that bronchial hyperreactivity can be reduced by antibiotic treatment. '8 Of the 10 patients with bronchiectasis who had bronchial hyperreactivity, four were hyperreactive to histamine only, three were hyperreactive to methacholine only, and three were hyperreactive to both agents. Recent work in both asthmatic2' and normal subjects22 suggests that inhalation tests with these two agents may measure different phenomena, and the relative lack of overlap in bronchial hyperreactivity to these agents in bronchiectasis is consistent with this view.
Regardless of the mechanism underlying bronchial hyperreactivity in bronchiectasis, the increased prevalence suggests that it may have a role in the pathogenesis of the disease, possibly by impairing clearance mechanisms and thereby contributing to a vicious circle ofmicrobial colonisation and inflammation.
